The novel compound Sul-121 inhibits airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease

Bing Han1,2, Wilfred J. Poppinga1,2, Haoxiao Zuo1,2, Annet B. Zuidhof2, I. Sophie T. Bos3, Marieke Smit1, Pieter Vogelaar1, Guido Krenning4, Robert H. Henning5, Harm Maarsingh6, Andrew J. Halayko7, Bernard van Vliet3, Stef Stienstra3, Adrianus Cornelis van der Graaf3, Herman Meurs1,2 & Martina Schmidt1,2

COPD is characterized by persistent airflow limitation, neutrophilia and oxidative stress from endogenous and exogenous insults. Current COPD therapy involving anticholinergics, β2-adrenoceptor agonists and/or corticosteroids, do not specifically target oxidative stress, nor do they reduce chronic pulmonary inflammation and disease progression in all patients. Here, we explore the effects of Sul-121, a novel compound with anti-oxidative capacity, on hyperresponsiveness (AHR) and inflammation in experimental models of COPD. Using a guinea pig model of lipopolysaccharide (LPS)-induced neutrophilia, we demonstrated that Sul-121 inhalation dose-dependently prevented LPS-induced neutrophilia (up to ~60%) and AHR (up to ~90%). Non-cartilaginous airways neutrophilia was inversely correlated with blood H2S, and LPS-induced attenuation of blood H2S (~60%) was prevented by Sul-121. Concomitantly, Sul-121 prevented LPS-induced production of the oxidative stress marker, malondialdehyde by ~80%. In immortalized human airway smooth muscle (ASM) cells, Sul-121 dose-dependently prevented cigarette smoke extract-induced IL-8 release parallel with inhibition of nuclear translocation of the NF-κB subunit, p65 (each ~90%). Sul-121 also diminished cellular reactive oxygen species production in ASM cells, and inhibited nuclear translocation of the anti-oxidative response regulator, Nrf2. Our data show that Sul-121 effectively inhibits airway inflammation and AHR in experimental COPD models, prospectively through inhibition of oxidative stress.

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide, which results a significant economic and social burden1. It is characterized by persistent and progressive airflow limitation and prominent neutrophilic airway inflammation1,2. Currently, reduction of COPD symptoms is achieved mainly with (a combination of) anticholinergics, β2-adrenoceptor agonists and glucocorticosteroids1. However, the current medications fail to reduce the progression of COPD and have even been associated with fatal side effects3–6.

Oxidative stress, caused by an anti-oxidant/oxidant imbalance that leads to increased generation of reactive oxygen species (ROS), is believed to play an important role in the pathogenesis of COPD5. ROS derived from exogenous (environmental pollution, cigarette smoke) or endogenous (inflammatory cells, such as neutrophils)
insult, promote the activation of the pro-inflammatory transcription factor nuclear factor (NF)-κB in structural lung cells including airway smooth muscle cells. Activation of NF-κB results in increased secretion of inflammatory cytokines such as interleukin (IL)-89–11, which recruit inflammatory cells, including neutrophils. Moreover, ROS trigger the peroxidative breakdown of lipids, a process implicated in lung injuries due to increased airway epithelial permeability. ROS have also been implicated as an important cause of steroid resistance in COPD. Targeting oxidative stress might be a beneficial approach for the management of COPD. Although evidence for clear clinical benefit is currently lacking, many anti-oxidative strategies using anti-oxidants or pharmacological agents have shown promising effects in COPD.

Due to its anti-oxidative capacities, the gasotransmitter hydrogen sulfide (H2S), synthesized by enzymes such as cystathionine β synthetase (CBS), has been proposed as a potential COPD treatment. By contrast, some studies indicated that its redox potential may provoke pro-inflammatory responses, for instance, oxidative stress originated from activated neutrophils can convert H2S to sulfite, which is considered an inflammatory mediator in airway diseases. Therefore, the usage of H2S or its donors to treat COPD is still under debate.

One mechanism that could underpin an anti-oxidant response to H2S is the activation of nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that increases the expression of anti-oxidant proteins in structural airway cells, including smooth muscle cells. Indeed, H2S is able to activate Nrf2 both in vivo in mouse models of lung injury and in vitro in embryonic fibroblasts.

Recently, we developed a novel class of pharmacological compounds of which Sul-121 (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl (piperazin-1-yl) methanone, Fig. 1A) is one of its leads with promising cell protective effects due to anti-oxidant capacities. In the present study, we explored the pharmacological potential of Sul-121 in vitro and in vivo experimental models of COPD. We report that Sul-121 prevents lipopolysaccharide (LPS)-induced neutrophilia, hyperresponsiveness (AHR) and oxidative stress in guinea pigs. In addition, Sul-121 reduces the cigarette smoke-induced release of IL-8 in cultured human airway smooth muscle (ASM) cells, which is accompanied by a reduction in cellular ROS production and nuclear translocation of Nrf2.

**Results**

**Effects of Sul-121 on LPS-induced AHR.** In line with earlier reports, we observed increased airway responsiveness to histamine 2 and 3 hours after LPS instillation, with PC100 values (the provocation concentration of histamine causing a 100% increase in pleural pressure (Ppl)) at these time points significantly lower than that for LPS-naïve animals that received only saline instillation (Fig. 1B). Although inhaled Sul-121 did not affect airway responsiveness in LPS-naïve control animals (Fig. 1B), it did prevent LPS-induced AHR in a dose-dependent manner up to 90% (Fig. 1C). At 30 mM (nebulizer concentration), Sul-121 almost fully prevented LPS-induced AHR (0.89 ± 0.09, p < 0.01; Fig. 1C). In line with our observation that Sul-121 did not affect airway responsiveness in LPS-naïve, saline-challenged animals, it also did not affect methacholine-induced contraction of bovine tracheal smooth muscle strips (Supplementary Fig. 1A). This finding strongly suggests that Sul-121 does not have a direct effect on airway smooth muscle tone.

**Effects of Sul-121 on LPS-induced Neutrophilia in BALF and Airway Tissue.** As expected, LPS challenge significantly increased the number of lung neutrophils in both cartilaginous (from 3.0 ± 0.8 to 19.8 ± 4.2 cells/mm basement membrane) and non-cartilaginous airways (from 4.7 ± 0.5 to 8.008 ± 1.099 cells/mm basement membrane), which was largely prevented by 30 mM Sul-121 in both airway categories (cartilaginous airways: 7.340 ± 2.402 cells/mm basement membrane; non-cartilaginous airways: 3.834 ± 0.824 cells/mm basement membrane; p < 0.01 both; Fig. 2A–C). Similar to the neutrophil changes in the airways, LPS induced a significant increase of neutrophils in bronchoalveolar lavage (BAL) fluids (BALFs) (from 0.07 ± 0.02 to 2.28 ± 0.66 × 10^7 cell number retrieved from the BAL; 0.457; Fig. 2D). Inhalation of Sul-121 dose-dependently prevented LPS-induced neutrophilia by up to 60% using 30 mM Sul-121 (to 0.91 ± 0.30 × 10^7 cell number retrieved from the BAL; p < 0.001; Fig. 2D). Sul-121 was without effect on basal neutrophil numbers in the lungs of saline challenged, LPS-naïve animals (Fig. 2D).

**Blood H2S level and Lung CBS expression.** H2S may have a protective role in inflammatory airway diseases. LPS challenge tended to decrease levels of serum H2S (from 342 ± 99 to 134 ± 56 × 10^-7 M), an effect prevented in guinea pigs pretreated with 30 mM Sul-121 (360 ± 157 × 10^-7 M; Fig. 3A). As shown in Fig. 3B, in both LPS-naïve, saline challenged and LPS challenged animals we found an inverse correlation between serum H2S levels and the number of neutrophils in non-cartilaginous airways (p = 0.041, r = 0.45). Neither immunohistochemistry nor western blotting revealed any difference in the abundance of the H2S producing enzyme, CBS, in the lungs of animals in any of our study groups (Fig. 3C,D). Over all, our data suggest that Sul-121 protects concomitant loss of serum H2S and against the accumulation of lung neutrophils that are otherwise induced by LPS challenge.

**Lung Nrf2 expression and MDA Levels.** Neither LPS nor Sul-121, alone or in combination altered the expression of the anti-oxidant transcription factor Nrf2 expression in lung homogenates (Fig. 4A). Polysaturated lipids can be degraded under oxidative stress leading to the formation of MDA. We therefore analyzed oxidative stress in lung tissue by measuring total MDA levels. LPS induced a 2-fold increase in MDA abundance (from 0.06 ± 0.01 to 0.12 ± 0.01 μmol/g protein; p < 0.01), confirming that oxidative stress had developed, and 30 mM Sul-121 fully prevented the LPS-induced MDA in lungs (0.07 ± 0.01 μmol/g protein; p < 0.05; Fig. 4C). Moreover, we found a positive correlation between lung MDA level and airway neutrophil number (p = 0.3234, r = 0.457; Fig. 4D). Taken together, these findings indicate that Sul-121 may at least partially, exert its protective effects in the lung by normalization of LPS-induced oxidative stress.
**IL-8 Release and p65 Nuclear Translocation in hTERT Cells.** The mechanisms by which Sul-121 may decrease airway neutrophilia were further studied in vitro using human ASM cells, which we have previously shown, and confirm here, to be capable of expressing and releasing abundant IL-8 in response to challenge with CSE by about 5-fold above basal (34 ± 13 pg/ml)⁹,¹⁰ (Fig. 5A). Treatment of cells with Sul-121 dose-dependently reduced 15% CSE-induced IL-8 release up to 90%, with 300 μM Sul-121 almost fully abrogating IL-8 release (p < 0.001); an effect on par with that elicited by 1 μM fenoterol, a first line COPD therapeutic²⁸ (Fig. 5A). Cell viability was not compromised by any concentrations of Sul-121 (Fig. 5B). CSE exposure significantly increased nuclear translocation of the NF-κB subunit, p65, an effect that was fully prevented by Sul-121 (from 255 ± 46 to 126 ± 12 fluorescence % of vehicle; p < 0.01; Fig. 5C,D).
ROS production and Nrf2 nuclear translocation in ASM cells.

Sul-121 (300 μM) reduced ROS levels in 2 mM H$_2$O$_2$ (from 177 ± 17 to 123 ± 4.9 fluorescence % of vehicle; p < 0.001) or 15% CSE (from 183 ± 12 to 136 ± 6.9 fluorescence % of vehicle; p < 0.001) solutions under cell-free condition (Fig. 6A). In addition, Sul-121 completely abolished in a dose-dependent manner ROS levels in 5 μM H$_2$O$_2$ (Fig. 6B), indicating that Sul-121 normalizes exogenous ROS in all experimental conditions. Thus the effects of Sul-121 on cell responses are likely due to direct effects on cellular oxidative stress and associated cell responses. Indeed, Sul-121 reduced endogenous ROS production by human ASM cells to the same degree as the broadly effective ROS inhibitor, 10 mM N-acetyl-L-cysteine (NAC; to 62 ± 6.4 and 69 ± 5.7 fluorescence % of vehicle, respectively; Fig. 6C). However,

**Figure 2. Effects of Sul-121 on LPS-induced neutrophilia in BALF, blood and airway tissue.** Guinea pigs were treated for 3 min by inhalation of vehicle or Sul-121 (3 or 30 mM nebulizer concentration) 30 min before intranasal instillation of 300μl saline or LPS (5 mg/ml) at 0 h. After animal termination at 25 h, BAL were performed, and blood and lungs were collected for further analysis. Neutrophils were stained with TNAP (red staining, arrows) in transverse frozen cross-sections of the lung. Representative images are shown (A), magnification: 10X, inset, 20X). Neutrophils in cartilaginous (B) and non-cartilaginous airways (C) on sections were quantified in the adventitia and sub-mucosa, and expressed as the number of positively stained cells per mm basement membrane length. Neutrophil numbers were determined in BALF (D) and blood (E). N = 4–6. (B,C,D) **p < 0.01, ***p < 0.001; two way ANOVA with bonferroni post-tests.
Sul-121, but not NAC, significantly reduced 0.1 μM phorbol 12-myristate 13-acetate (PMA)-induced ROS production by ASM cells (from 132 ± 8.3 to 88 ± 4.4 fluorescence % of vehicle; p < 0.001; Fig. 6C).

We found that 15% CSE and 10 μg/ml LPS exposure significantly increased the nuclear translocation of the anti-oxidant transcription factor Nrf2 (CSE: 368 ± 52 fluorescence % of vehicle, p < 0.001; LPS: 338 ± 88 fluorescence % of vehicle, p < 0.001; Fig. 7A,B) as measured by immunofluorescence. Notably, 300 μM Sul-121 completely prevented Nrf2 translocation to the nucleus induced by both CSE (127 ± 16 fluorescence % of vehicle; p < 0.001; Fig. 7A,B) and LPS (118 ± 13 fluorescence % of vehicle; p < 0.01; Fig. 7A,B).

Discussion
COPD is characterized by persistent and progressive airflow limitation associated with chronic pulmonary inflammation⁴. Although often underestimated in clinical assessment, AHR is an important characteristic of COPD²⁹ that associates with accelerated lung function decline³⁰,³¹. There is a strong association between AHR and accumulation of lung neutrophils³², which are associated with production of ROS and a number of potent pro-inflammatory cytokines³,³². In our present study, using a guinea pig model of LPS-induced neutrophilia that mimics that in COPD and promotes the development of AHR, we show that Sul-121 dose-dependently prevents AHR induced by intranasal instillation of LPS in vivo. The acute LPS-challenge model we employ induces marked accumulation of lung neutrophils, a feature that correlates strongly with clinical outcomes³³,³⁴. Here we report from in vitro and in vivo studies that though Sul-121 has no direct bronchodilatory effects, it does strongly inhibit the development of AHR, primarily by inhibiting LPS-induced lung inflammation. Indeed, inhaled Sul-121 prevents LPS-induced lung neutrophilia, confirmed in BALF and in both cartilaginous and non-cartilaginous airways, as well as the induction of markers of oxidative stress in the lungs, demonstrating that Sul-121 possesses significant anti-oxidant and anti-inflammatory properties.

As a potent neutrophil chemoattractant and activator³, levels of IL-8 in the lungs are strongly correlated with neutrophil number in COPD patients³⁵,³⁶. We report that Sul-121 dose-dependently reduces CSE-induced IL-8 release from human ASM cells in vitro, potentially explaining the capacity for inhaled Sul-121 to block
LPS-induced lung neutrophilia in vivo. NF-κB is involved in the transcription of a variety of pro-inflammatory genes, including IL-8, and is activated by CSE9,10. The activation of NF-κB is associated with the translocation of its p65 subunit to the nucleus, subsequently triggering transcription of inflammatory cytokines and chemokines37. We show that Sul-121 pre-treatment effectively prevents CSE-induced p65 nuclear translocation in human ASM cells, an effect that parallels suppression of CSE-induced IL-8 release. Taken together, our current findings indicate that Sul-121 may prevent airway neutrophilic inflammation by decreasing IL-8 release upon inhibition of NF-κB activation and subsequent nuclear translocation.

Oxidative stress plays a central role in inflammatory responses in COPD7. NF-κB can be activated by oxidative stress, leading to downstream inflammatory responses38. Therefore, the anti-inflammatory effect of Sul-121 could be explained by an anti-oxidant effect. Nrf2 is a nuclear factor that controls cellular anti-oxidative responses39. Under favorable physiological conditions, the Nrf2 activity is suppressed by Keap1, a cytosolic protein binding partner that prevents Nrf2 nuclear translocation. Under conditions of oxidative stress, Keap1 dissociates from, and permits nuclear translocation of Nrf240. Subsequently, Nrf2-induced transcription of anti-oxidant genes initiates adaptive responses that can counteract oxidative stress39. We now report that CSE, as well as LPS, exposure of human ASM cells induces Nrf2 nucleus translocation, and that Sul-121 significantly decreases Nrf2 nucleus translocation induced by both CSE and LPS. Although these findings at first seem contradictory, they actually do support an anti-oxidant role for Sul-121 as they diminish the requirement for endogenous pathways to increase the transcription of anti-oxidative stress genes. In support of an anti-oxidant property for Sul-121, we report that it significantly reduces both exogenous ROS levels in pro-oxidant treatments (e.g. CSE and H2O2), as well as endogenous ROS produced by ASM cells in response to PMA. Taken together, our findings support a hypothesis that Sul-121 exerts anti-inflammatory effects through normalization of oxidative stress.
Accordingly, LPS-induced elevation of MDA, a product of peroxidative breakdown of polyunsaturated fatty acids, is effectively reduced in guinea pigs pretreated with Sul-121. Importantly, lung MDA levels correlate with lung neutrophil infiltration induced by LPS in vivo. The anti-oxidant properties of Sul-121 may explain, at least in part, its capacity in the present study to suppress LPS-induced AHR, as oxidative stress has been directly implicated to underpin pathogenesis leading to decreased lung function. In addition, peroxidative breakdown of polyunsaturated fatty acids contributes to impairment of the epithelial integrity, which can contribute to increased transmigration of neutrophils to the airway lumen. Since CSE has been shown to impair airway epithelial integrity in vitro, it is tempting to speculate that the prevention of LPS-induced airway neutrophilia by...
Sul-121 may be associated with maintenance of epithelial integrity due to its anti-oxidative properties. Our work supports future studies to fully investigate this possibility. Notably, H$_2$S reportedly protects against LPS-induced lung injury. Several studies have focused on the effects of exogenous H$_2$S donors on inflammation. Nonetheless, little is known about the relationship between airway inflammation and endogenous H$_2$S production. Serum H$_2$S levels may be decreased in COPD patients during acute exacerbation, and patients requiring antibiotics due to lower respiratory tract infections exhibit significantly reduced serum H$_2$S levels compared subjects not requiring antibiotics. In line with these findings, we

Figure 6. Effects of Sul-121 on ROS production. Under cell-free condition, carboxy-H2DCF-DA (0.1 μM) was incubated for 40 min with 300 μM Sul-121 in the absence and presence of H$_2$O$_2$ (2 mM) or CSE (15%). ROS was measured by the intensity of DCF emission (A). Alternatively, DHE (5 μM) was incubated for 1 hour with Sul-121 (1–100 μM) in the absence and presence of H$_2$O$_2$ (5 μM). ROS was measured by the intensity of DHE emission (B). Immortalized human ASM cells were incubated with 300 μM Sul-121 in the absence and presence of PMA (0.1 μM) for 2 hours. 10 mM NAC served as positive control. After removal of the supernatant, cells were incubated with carboxy-H2DCFDA (0.1 μM) for 1 h. ROS was measured by the intensity of DCF emission (C). (A) N = 12; **p < 0.01, ***p < 0.001; two way ANOVA with Bonferroni post-tests. (B) N = 3, ***p < 0.001, compared to Basal; one way ANOVA with Bonferroni post-tests. **p < 0.01, ***p < 0.001, compared to H$_2$O$_2$ treatment; one way ANOVA with Bonferroni post-tests. (C) N = 4; *p < 0.05, **p < 0.01, ***p < 0.001; two way ANOVA with Bonferroni post-tests.
report that LPS challenge induces a trend towards reduced serum H$_2$S, and serum H$_2$S levels negatively correlate with neutrophil number in non-cartilaginous (p = 0.0406). The oxidation of blood H$_2$S to its pro-inflammatory sulfite form occurs during oxidative stress generated upon exposure of neutrophils to LPS. Therefore, we speculate that LPS-induced oxidative stress leads to loss of serum H$_2$S in the guinea pig model we have employed. Interestingly, resistance to corticosteroid therapies in COPD patients has been attributed to the imbalance of acetylation-deacetylation states of histones due to the impact of oxidative stress on histone deacetylase. Thus, it would be interesting to study whether Sul-121 prevents or reverses corticosteroid resistance in experimental models of COPD.

In conclusion, we show that Sul-121 reduces neutrophilic inflammation and AHR in an LPS-induced experimental model of COPD in vivo, probably due to the reduction of oxidative stress as well as inhibition of NF-κB and Nrf2 activation. These findings support future work to determine the potential for Sul-121 as a candidate for treatment of COPD.

**Methods**

**Animals.** Outbred male, specified pathogen-free Dunkin Hartley guinea pigs (Harlan, Heathfield, UK) weighing 350–450 g were used. Guinea pigs were randomly divided into indicated experimental groups with 4–6 guinea pigs per group. All in vivo protocols described in this study were approved by the University of Groningen (Groningen, The Netherlands) Committee for Animal Experimentation. All the methods were carried out in accordance with the approved guidelines.
Animal Model of COPD. Guinea pigs were intranasally instilled with LPS (Sigma, L-2880) to induce neutrophilic airway inflammation and AHR24–26. Guinea pigs were held in upright position while 300μl LPS (5 mg/ml sterile saline) was slowly instilled intranasally and kept in the upright position for an additional 2 min to allow sufficient spreading of the fluid throughout the airways. Control animals were instilled with 300μl sterile saline.

Experimental In Vivo Protocols. As shown in Fig. 1A, 30 min before LPS or saline instillation animals were treated by inhalation of aerosolized vehicle (2% dimethyl sulfoxide and 0.2% Tween80 in saline) or Sul-121 solutions (3 or 30 mM, nebulizer concentrations) for 3 min in a 9-liter Perspex cage53. A DeVilbiss nebulizer (type 646) driven by an airflow of 8 l/min provided the aerosol with an output of 0.33 ml/min. Airway responsiveness to histamine was measured 24 hours before (basal) and 1, 2, 3, 6 and 24 hours after LPS/saline instillation by lung function measurements as described below. At 24 hours after LPS challenge, BAL was performed to assess infiltrating cell infiltration in the airways.

In a separate protocol, guinea pigs inhaled Sul-121 (30 mM, 3 min) or vehicle 30 min before LPS or saline challenge, followed by blood and lung tissue collection at 25 hours later. Blood was collected by heart puncture and stored in EDTA coated tubes. Neutrophil numbers were determined in blood. Serum was obtained by centrifuging (2000 rcf, 10 min) to quantify levels of Sul-121 and H$_2$S. Lung tissue was snap frozen and used for histology (neutrophils) and immunohistochemistry (CBS, Nrf2) using transverse frozen cross-sections (5μm) of the upper right lung lobe, and for Western blotting (CBS, Nrf2) and malondialdehyde (MDA) measurements using homogenates of the other parts of the lungs.

Measurement of Airway Responsiveness to Histamine. Lung function was assessed by online measurement of pleural pressure (Ppl) under conscious and unrestrained conditions53. In short, a small fluid-filled latex balloon catheter was surgically implanted inside the thoracic cavity and connected to a pressure transducer (TXX-R; Viggo-Spectramed, Bilhoven, The Netherlands) via an external saline-filled cannula. Ppl was continuously measured using an online computer system. Changes in Ppl are linearly related to changes in airway resistance and serves as a sensitive index for stimulus-induced bronchoconstriction53.

Histamine provocations were performed by inhalation of stepwise increasing concentrations of histamine (Sigma, H-7250) in saline (0, 25, 50, 75, 100, 125 and 150μg/ml). Solution were nebulized for maximally 3 minutes with intervals of 7 minutes, until the Ppl was increased by more than 100% above baseline for at least 3 consecutive minutes. The provocation concentration of histamine causing a 100% increase in Ppl (PC100) was derived by linear interpolation of the concentration-Ppl curve and used as an index for airway responsiveness. Animals were habituated to the experimental conditions as previously described53.

Neutrophil Counting in BAL Fluid and Lung Tissue. BAL was performed as previously described54. After anesthesia with pentobarbital (Euthasol 20% i.p.), the trachea was exposed and cannulated, and the lungs were gently lavaged using 5 ml of sterile saline (37 °C), followed by three subsequent aliquots of 8 ml of saline. The recovered BALFs were kept on ice and centrifuged at 200 rcf for 10 min at 4 °C. Pellets were re-suspended into a final volume of 1 ml phosphate-buffered saline (PBS), and a CASY cell counter (Model TT; Innovatis, Reulingen, Germany) was used to count total cell numbers. For neutrophil determination, cytopsin preparations were stained with May-Grünwald and Giemsa stain54. Cell differentiation was performed by counting at least 400 cells in duplicate.

Tissue nonspecific alkaline phosphatase (TNAP) staining was used to identify neutrophils on frozen lung sections.55 Sections were rinsed in a TRIS-base buffer (pH 7.6) for 2 min, and then incubated for 5 min in a TRIS-base buffer (pH 9.0) containing 1 mg/ml naphthol AS-BI phosphate (Sigma, N2125) and 1 mg/ml Fast Red TR Salt hemi (zinc chloride) salt (Sigma, F8764). Sections were rinsed in a TRIS-base buffer (pH 9.0) for 2 min, counterstained with haematoxylin (Sigma, GHS3) for 1 min, and mounted in Kaiser’s glycerol gelatin. Airway neutrophils were counted in the adventitia and sub-mucosa, and expressed as the number of positively stained cells per mm basement membrane length.

CBS and Nrf2 Immunohistochemistry. After fixation in acetone, guinea pig lung sections were blocked in 3% hydrogen peroxide (H$_2$O$_2$) for 30 min, followed by 1 hour blocking in 10% serum (normal rabbit serum (Dako, X0902) for CBS, normal goat serum (Dako, X0907) for Nrf2). Sections were then incubated with primary antibodies (Santa–Cruz, sc-271866, 1:50 for CBS; Abcam, ab31163, 1:100 for Nrf2) for 1 hour at room temperature. Primary antibodies were visualized using horseradish peroxidase-labelled secondary antibodies (1:100) and diaminobenzidine. Sections were counterstained with haematoxylin (Sigma, GH33) for 1 min and mounted in Kaiser’s glycerol gelatin.

CBS and Nrf2 Western Blotting. Guinea pig lung homogenates were prepared by pulverizing lung tissue in liquid nitrogen, followed by ultra-sonication in RIPA buffer (composition: 50 mM Tris, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% nonyl phenoxypolyethoxyethanol), supplemented with 1 mM Na3VO4, 1 mM NaNF, 1.06 mg/ml 3-glycerolphosphate, 10μg/ml aprotinin, 10μg/ml leupeptin, and 7μg/ml pepstatin A. Lysates were centrifuged at 12000 rcf for 20 min at 4 °C, and supernatants were collected.

Protein content was determined using the Pierce BCA protein assay (ThermoFisher, 23225). Equal amounts of protein were separated on a 10% polyacrylamide gel, transferred onto nitrocellulose membranes, blocked with 1X Roti block reagent, and incubated overnight with primary antibodies (Santa–Cruz, sc-271886, CBS: 1:100; Abcam, ab31163, Nrf2: 1:1000; Santa–Cruz, sc–47724, GAPDH: 1:400) at 4°C. After washing, membranes were incubated with horseradish peroxidase-labelled secondary antibodies. Protein bands were visualized using Western lightning plus ECL (PerkinElmer, NEL105001EA) and quantified using Image J 1.48v. CBS and Nrf2 were normalized to GAPDH.
MDA Measurement. MDA concentrations in guinea pig lung homogenates was measured by the thiobarbituric acid reactive substances assay. Lung lysates were mixed with 10% trichloroacetic acid (Sigma, T9159; 1:1, v/v) and centrifuged at 2,200 x g for 15 min for protein removal. Samples were mixed with 6.7 g/l thiobarbituric acid (Sigma, T5508; 1:1, v/v) and heated at 95°C. MDA levels were determined by measuring absorption at 550 nm. The standard curve was made by measuring a series of gradually diluted 1,1,3,3-tetramethoxypropane (Sigma, 108383) solutions. MDA levels in lung homogenates were expressed as μmol MDA per g protein.

H2S Measurement. H2S levels were determined by measuring sulfide levels in alkaline liquid solutions. Equal amounts of serum or cell culture supernatant and SOAB buffer (390 mM sodium salicylate, 9.2 mM ascorbic acid, 531 mM NaOH in H2O) were mixed. The resulting sulfide levels were measured using an ISM-146S electrode (Lazar, Los Angeles, USA) in combination with a 6230N mV meter (Jenco, San Diego, USA).

ASM Cell Culture. Three human airway smooth cell lines, immortalized by human telomerase reverse transcriptase (hiTERT) were used for all the experiments. The primary cultured human airway smooth cells used to generate each hiTERT immortalized cell line were prepared as described previously. Informed consent was obtained from all subjects. All procedures were in accordance with the relevant guidelines and approved by the Human Research Ethics Board of the University of Manitoba. The cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Life technologies, 11965-092) containing heat-inactivated fetal bovine serum (10% vol/vol), streptomycin (50 U/ml), penicillin (50 mg/ml) in a humidified atmosphere at 37°C in air/CO2 (95%;5% vol/vol).

Cigarette Smoke Extract Preparation. Cigarette smoke extract (CSE) was freshly prepared by pumping the smoke from two combusted 3R4F research cigarettes (Reference Cigarette Program, University of Kentucky) through 25 ml of serum-free DMEM. This was designated as 100% CSE.

IL-8 Measurement. hiTERT-ASM cells were plated on 24-well plates. After grown to confluence, cells were treated with the indicated concentrations of the Sul-121 in the absence and presence of 15% CSE for 24 hours in serum-free DMEM. Culture medium was collected to measure IL-8 concentrations using an IL-8 enzyme-linked immunosorbent assay (ELISA) kit (Pelikine, M1918) according to the manufacturer’s instructions. Fenoterol (Boehringer Ingelheim, 217-742-8, 1 μM) treatment was used as a positive control. Cells were trypsinized for trypan blue cell counting to determine cell viability. Data represent from 7 to 24 experiments.

Nrf2 and p65 Immunofluorescence. ASM cells were plated on cover slips in 12-well plate. After grown to confluence, cells were treated with 300 μM Sul-121, with or without 15% CSE or 10 μg/ml LPS (Sigma, L-2880), for 2 hours. Cells were then fixed with a solution containing 4% paraformaldehyde and 4% sucrose for 15 min at room temperature, followed by treatment with 0.3% Triton X-100 for 5 min at room temperature. Cells were blocked for 1 hour at room temperature with PBS containing 5% bovine serum albumin and 2% donkey serum. Cells were then incubated overnight at 4°C with primary antibodies against Nrf2 (Abcam, ab31163, 1:100) and p65 (Cell Signaling, #3033S, 1:20). The next day, cells were washed with PBS and incubated with secondary antibodies (1:500) for 1 hour at room temperature. After wash with PBS, nuclei were stained with Hoechst (Invitrogen, H3570, 1:10000) for 5–10 sec, immediately followed by two quick and four 10 min washing steps with ultra-pure water. After staining, coverslips were mounted using ProLong® Gold Antifade Mountant reagent (Life Technologies, P36930) and imaged using an Olympus AX70 microscope equipped with digital image capture system (ColorView Soft System with Olympus U CMAD2 lens, Olympus Corporation, Tokyo, Japan). The background corrected fluorescence measurements were performed with Image J 1.48v. Data represent from 4 to 5 experiments.

ROS Measurement. The 7′-dichlorofluorescein-diacetate (DCF-DA) fluorescence method was used for the determination of ROS level. 6-carboxy-2′,7′-dichloro-dihydrofluorescein diacetate, di(acetoxymethyl ester) (Carboxy-H2DCFDA, Life technologies, C-2938, 0.1 μM) was dissolved in DMEM and supplemented with SUL-121 (1–100 μM) treatment was used as a positive control. Cells were trypsinized for 2 hours. 10 mM NAC (Sigma, A9165) served as positive control. After removal of the supernatant, cells were incubated with 0.1 μM carboxy-H2DCFDA for 1 hour and ROS production was measured as described above. Data represent 3–12 experiments.

Statistics. Data represent means ± SEM, from n experiments. Statistical significance of differences was evaluated by one-way or two way ANOVA with Bonferroni post-hoc tests, or by two tailed Student’s t-test using Prism 5 software. Pearson’s correlation tests were also performed by using Prism5. Differences were considered to be statistically significant when p < 0.05.

All the figures and pictures were created by authors of this paper.
All in vivo protocols described in this study were approved by the University of Groningen (Groningen, The Netherlands) Committee for Animal Experimentation. All the methods were carried out in accordance with the approved guidelines.

For experiments involving human samples, informed consent was obtained from all subjects. All procedures were in accordance with the relevant guidelines and approved by the Human Research Ethics Board of the University of Manitoba.

References
1. GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2015).
2. Hoenderdonk, K. & Condliffe, A. The neutrophil in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 48, 531–539 (2013).
3. Barnes, P. J., Shapiro, S. D. & Pawels, R. A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur. Respir. J. 22, 672–688 (2003).
4. Broadley, K. J. Beta-adrenergic responses of the airways: for better or worse? Eur. J. Pharmacol. 533, 15–27 (2006).
5. Barnes, P. J. Immunology of asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 8, 183 192 (2008).
6. Matera, M. G., Rogliani, P. & Cazzola, M. Mucociliary receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 15, 961 977 (2014).
7. Kirkham, P. A. & Barnes, P. J. Oxidative stress in COPD. Chest 144, 266–273 (2013).
8. Luo, S.-F. et al. Activation of ROS/NF-kappaB and Ca2+/CaM kinase II are necessary for VCAM-1 induction in IL-1beta-treated human tracheal smooth muscle cells. Toxicol. Appl. Pharmacol. 237, 8–21 (2009).
9. Oenema, T. A. et al. Pro-inflammatory mechanisms of muscarinic receptor stimulation in airway smooth muscle. Respir. Res. 11, 130 (2010).
10. Oldenburger, A. et al. Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease. PloS One 7, e31574 (2012).
11. Pera, T. et al. Role for TAK1 in cigarette smoke-induced proinflammatory signaling and IL-8 release by human airway smooth muscle cells. Am. J. Physiol. Cell. Mol. Physiol. 303, 1272–8 (2012).
12. Shintani, Y. et al. Nuclear factor erythroid 2-related factor 2 (Nrf2) regulates airway epithelial barrier integrity. Allergol. Int., doi: 10.1016/j.alit.2015.06.004 (2015)
13. Barnes, P. J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 131, 636–645 (2013).
14. Rahman, I. Antioxidant therapies in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 1, 15–29 (2006).
15. Chen, Y. & Wang, R. The message in the air: hydrogen sulfide metabolism in chronic respiratory diseases. Respir. Physiol. Neurobiol. 184, 130–138 (2012).
16. Faller, S. et al. Inhaled hydrogen sulfide protects against lipopolysaccharide-induced acute lung injury in mice. Med. Gas Res. 2, 26 (2012).
17. Mitsuhashi, H. et al. Oxidative stress-dependent conversion of hydrogen sulfide to sulfite by activated neutrophils. Shock Augusta Ga 24, 529–534 (2005).
18. Mitsuhashi, H. et al. Increased levels of serum sulfite in patients with acute pneumonia. Shock Augusta Ga 21, 99–102 (2004).
19. Michaeloudes, C., Chang, P.-J., Petrou, M. & Chung, K. F. Transforming growth factor-β and nuclear factor E2–related factor 2 regulate antioxidant responses in airway smooth muscle cells: role in asthma. Am. J. Respir. Crit. Care Med. 184, 894–903 (2011).
20. Han, W., Dong, Z., Dimitropoulou, C. & Su, Y. Hydrogen sulfide ameliorates tobacco smoke-induced oxidative stress and emphysema in mice. Antioxid. Redox Signal. 15, 2121–2134 (2011).
21. Francis, R. C., Vaporidi, K., Bloch, K. D., Ichinose, F. & Zapol, W. M. Protective and Detrimental Effects of Sodium Sulfide and Hydrogen Sulfide in Murine Ventilator-induced Lung Injury. Anesthesiology 115, 1021–1022 (2011).
22. Hourihan, J. M., Kenna, J. G. & Hayes, J. D. The gasotransmitter hydrogen sulfide induces Nrf2-target genes by inactivating the keap1 Neh2 domain. Genes Dev. 13, 76–86 (1999).
The novel compound Sul-121 inhibits airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease. 

Sci. Rep. 6, 26928; doi: 10.1038/srep26928 (2016).

How to cite this article: Han, B. et al. The novel compound Sul-121 inhibits airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease. Sci. Rep. 6, 26928; doi: 10.1038/srep26928 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/